Oak Street Health (NYSE:OSH) had its target price decreased by Piper Sandler from $55.00 to $47.00 in a report released on Tuesday morning, The Fly reports. Piper Sandler also issued estimates for Oak Street Health’s Q4 2021 earnings at ($0.67) EPS, FY2021 earnings at ($1.89) EPS, Q2 2022 earnings at ($0.52) EPS, Q3 2022 earnings at ($0.68) EPS, FY2022 earnings at ($2.56) EPS, Q1 2023 earnings at ($0.65) EPS, Q2 2023 earnings at ($0.69) EPS, Q3 2023 earnings at ($0.74) EPS, Q4 2023 earnings at ($0.92) EPS, FY2023 earnings at ($3.00) EPS and FY2024 earnings at ($3.05) EPS.
OSH has been the subject of several other research reports. Cowen cut shares of Oak Street Health from an outperform rating to a market perform rating and reduced their price objective for the company from $48.00 to $25.00 in a research note on Monday, January 10th. Jefferies Financial Group began coverage on shares of Oak Street Health in a research report on Wednesday, October 20th. They set a buy rating and a $50.00 target price for the company. Morgan Stanley restated an equal weight rating and set a $33.00 target price (down previously from $44.00) on shares of Oak Street Health in a research report on Friday, December 17th. Truist Securities cut their target price on shares of Oak Street Health from $72.00 to $55.00 and set a buy rating for the company in a research report on Wednesday, October 13th. Finally, Zacks Investment Research upgraded shares of Oak Street Health from a sell rating to a hold rating in a research report on Tuesday, October 19th. Four investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Oak Street Health currently has a consensus rating of Buy and an average target price of $57.82.
Shares of NYSE OSH opened at $22.00 on Tuesday. The company has a quick ratio of 2.78, a current ratio of 2.78 and a debt-to-equity ratio of 5.88. Oak Street Health has a 52 week low of $21.56 and a 52 week high of $66.31. The firm has a 50-day moving average price of $32.75 and a 200 day moving average price of $44.62. The stock has a market capitalization of $5.30 billion, a price-to-earnings ratio of -13.58 and a beta of 1.14.
Oak Street Health (NYSE:OSH) last announced its quarterly earnings data on Monday, November 8th. The company reported ($0.49) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.47) by ($0.02). Oak Street Health had a negative net margin of 27.80% and a negative return on equity of 133.13%. The company had revenue of $388.70 million during the quarter, compared to analyst estimates of $357.53 million. During the same quarter last year, the business earned ($0.15) EPS. The firm’s revenue for the quarter was up 78.4% on a year-over-year basis. Equities research analysts expect that Oak Street Health will post -1.83 EPS for the current fiscal year.
In related news, insider Robert Guenthner sold 10,328 shares of the business’s stock in a transaction that occurred on Thursday, October 21st. The shares were sold at an average price of $45.75, for a total value of $472,506.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Geoffrey M. Price sold 72,500 shares of the business’s stock in a transaction that occurred on Tuesday, October 26th. The shares were sold at an average price of $45.24, for a total transaction of $3,279,900.00. The disclosure for this sale can be found here. In the last three months, insiders sold 401,541 shares of company stock valued at $16,002,409. Company insiders own 10.10% of the company’s stock.
A number of institutional investors have recently added to or reduced their stakes in OSH. Capital Research Global Investors purchased a new stake in Oak Street Health in the third quarter valued at approximately $139,805,000. Vanguard Group Inc. grew its stake in Oak Street Health by 48.2% during the second quarter. Vanguard Group Inc. now owns 8,682,834 shares of the company’s stock worth $508,554,000 after buying an additional 2,822,067 shares during the period. BlackRock Inc. grew its stake in Oak Street Health by 34.0% during the third quarter. BlackRock Inc. now owns 7,308,774 shares of the company’s stock worth $310,841,000 after buying an additional 1,854,780 shares during the period. Nuveen Asset Management LLC grew its stake in Oak Street Health by 94.7% during the second quarter. Nuveen Asset Management LLC now owns 3,123,370 shares of the company’s stock worth $182,936,000 after buying an additional 1,519,285 shares during the period. Finally, Millennium Management LLC grew its stake in Oak Street Health by 692.8% during the third quarter. Millennium Management LLC now owns 1,481,702 shares of the company’s stock worth $63,017,000 after buying an additional 1,294,810 shares during the period. Hedge funds and other institutional investors own 85.67% of the company’s stock.
About Oak Street Health
Oak Street Health, Inc, together with its subsidiaries, offers healthcare services to the patients in the United States. The company operates primary care centers for Medicare beneficiaries. As of December 31, 2020, it operated 79 centers in Illinois, Indiana, Michigan, Mississippi, New York, North Carolina, Ohio, Pennsylvania, Rhode Island, Tennessee, and Texas.
Read More: Why do companies issue convertible shares?